Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Coverage Initiated at Evercore

Equities research analysts at Evercore assumed coverage on shares of Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) in a research report issued on Wednesday. The firm set an “outperform” rating and a $46.00 price target on the stock. Evercore’s price objective would suggest a potential upside of 85.04% from the stock’s current price.

A number of other research analysts have also issued reports on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of Damora Therapeutics, Inc. Common Stock in a research note on Monday, December 29th. Guggenheim restated a “buy” rating and set a $40.00 price target (up from $36.00) on shares of Damora Therapeutics, Inc. Common Stock in a report on Tuesday, February 17th. Leerink Partners began coverage on Damora Therapeutics, Inc. Common Stock in a research report on Wednesday, January 7th. They issued an “outperform” rating and a $46.00 price target on the stock. Lifesci Capital upgraded Damora Therapeutics, Inc. Common Stock to a “strong-buy” rating in a research note on Monday, February 2nd. Finally, UBS Group began coverage on Damora Therapeutics, Inc. Common Stock in a research note on Tuesday, February 17th. They set a “buy” rating and a $45.00 target price for the company. Two investment analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $44.25.

Damora Therapeutics, Inc. Common Stock Stock Up 3.9%

Shares of NASDAQ:DMRA traded up $0.94 during trading on Wednesday, reaching $24.86. The stock had a trading volume of 11,972 shares, compared to its average volume of 235,911. The stock has a fifty day simple moving average of $26.97 and a two-hundred day simple moving average of $19.41. Damora Therapeutics, Inc. Common Stock has a 52 week low of $2.01 and a 52 week high of $38.33. The firm has a market capitalization of $1.50 billion, a price-to-earnings ratio of -2.05 and a beta of 1.42.

Institutional Trading of Damora Therapeutics, Inc. Common Stock

Institutional investors have recently bought and sold shares of the stock. Two Sigma Investments LP acquired a new position in Damora Therapeutics, Inc. Common Stock during the third quarter worth $76,000. Virtu Financial LLC acquired a new stake in shares of Damora Therapeutics, Inc. Common Stock in the 3rd quarter valued at $49,000. Connective Capital Management LLC bought a new stake in shares of Damora Therapeutics, Inc. Common Stock in the 3rd quarter worth about $100,000. Sigma Planning Corp bought a new stake in shares of Damora Therapeutics, Inc. Common Stock in the 4th quarter worth about $334,000. Finally, Geode Capital Management LLC acquired a new stake in shares of Damora Therapeutics, Inc. Common Stock during the 4th quarter worth about $266,000. Institutional investors and hedge funds own 14.20% of the company’s stock.

Damora Therapeutics, Inc. Common Stock Company Profile

Galecto Inc is a clinical‐stage biotechnology company developing small‐molecule therapies that target key pathways involved in fibrotic and malignant diseases. The company’s research focuses on inhibiting galectin‐3, an extracellular carbohydrate‐binding protein implicated in inflammation, fibrosis and tumor progression, as well as lysyl oxidase‐like 2 (LOXL2), an enzyme that crosslinks collagen and elastin in fibrotic tissue.

Its lead programs include GB0139, an inhaled galectin‐3 inhibitor in Phase II trials for idiopathic pulmonary fibrosis and other fibrosing lung diseases, and GB1211, an oral galectin‐3 inhibitor being evaluated for systemic fibrotic disorders.